How to keep high-risk studies ethical: classifying candidate solutions

Nir Eyal

doi:10.1136/medethics-2016-103428

How to keep high-risk studies ethical: classifying candidate solutions

Eyal, Nir

Journal of Medical Ethics , Volume 43 (2) – Feb 9, 2017

Abstract

This article lays out a wide spectrum of candidate ethical solutions for the challenge on which this JME symposium focuses: the benefit:risk ratio challenge to some early-phase HIV cure and remission studies. These candidate solutions fall into four categories: ones that seek to reduce risks in early-phase HIV cure and remission studies, ones that enhance the benefits for these studies’ participants (or show that those were adequate in the first place), ones that focus on participants’ free and informed consent to participate and ones according to whom the large benefits to non-participants can defeat considerations about individual participant net risks. In so doing, this article also structures the rest of the symposium.

References (68)

E. Emanuel, David Wendler, C. Grady (2000)

What makes clinical research ethical?

Australasian Journal of Dermatology, 42

Ardon Lyon (1989)

Ethics, Emotion and the Unity of the Self By Oliver Letwin London: Croom Helm, 1988, x + 132 pp., £22.50

Philosophy, 64

(LeventhalJ, AbecassisM, MillerJ, et al Chimerism and Tolerance Without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci Transl Med 2012;4:124ra28 10.1126/scitranslmed.3003509)

LeventhalJ, AbecassisM, MillerJ, et al Chimerism and Tolerance Without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci Transl Med 2012;4:124ra28 10.1126/scitranslmed.3003509, LeventhalJ, AbecassisM, MillerJ, et al Chimerism and Tolerance Without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci Transl Med 2012;4:124ra28 10.1126/scitranslmed.3003509

J. Kimmelman (2009)

Gene Transfer and the Ethics of First-in-Human Research: Introduction: gene transfer lost in translation

(DresserR Building an ethical foundation for first-in-human nanotrials. J Law Med Ethics 2012;40:802–8. 10.1111/j.1748-720X.2012.00708.x23289682)

DresserR Building an ethical foundation for first-in-human nanotrials. J Law Med Ethics 2012;40:802–8. 10.1111/j.1748-720X.2012.00708.x23289682

DresserR Building an ethical foundation for first-in-human nanotrials. J Law Med Ethics 2012;40:802–8. 10.1111/j.1748-720X.2012.00708.x23289682, DresserR Building an ethical foundation for first-in-human nanotrials. J Law Med Ethics 2012;40:802–8. 10.1111/j.1748-720X.2012.00708.x23289682

(HeySP, KimmelmanJ The risk-escalation model: a principled design strategy for early-phase trials. Kennedy Inst Ethics J 2014;24:121–39. 10.1353/ken.2014.001725109092)

HeySP, KimmelmanJ The risk-escalation model: a principled design strategy for early-phase trials. Kennedy Inst Ethics J 2014;24:121–39. 10.1353/ken.2014.001725109092

HeySP, KimmelmanJ The risk-escalation model: a principled design strategy for early-phase trials. Kennedy Inst Ethics J 2014;24:121–39. 10.1353/ken.2014.001725109092, HeySP, KimmelmanJ The risk-escalation model: a principled design strategy for early-phase trials. Kennedy Inst Ethics J 2014;24:121–39. 10.1353/ken.2014.001725109092

(VellemanJD Well-being and time. Pac Philos Q 1991;72:48–77.)

VellemanJD Well-being and time. Pac Philos Q 1991;72:48–77.

VellemanJD Well-being and time. Pac Philos Q 1991;72:48–77., VellemanJD Well-being and time. Pac Philos Q 1991;72:48–77.

(KoyfmanSA, AgrawalM, Garrett-MayerE, et al Risks and benefits associated with novel phase 1 oncology trial designs. Cancer 2007;110:1115–24. 10.1002/cncr.2287817628485)

KoyfmanSA, AgrawalM, Garrett-MayerE, et al Risks and benefits associated with novel phase 1 oncology trial designs. Cancer 2007;110:1115–24. 10.1002/cncr.2287817628485

KoyfmanSA, AgrawalM, Garrett-MayerE, et al Risks and benefits associated with novel phase 1 oncology trial designs. Cancer 2007;110:1115–24. 10.1002/cncr.2287817628485, KoyfmanSA, AgrawalM, Garrett-MayerE, et al Risks and benefits associated with novel phase 1 oncology trial designs. Cancer 2007;110:1115–24. 10.1002/cncr.2287817628485

F. Miller, A. Wertheimer (2007)

Facing Up to Paternalism in Research Ethics

Hastings Center Report, 37

J. Kimmelman, A. London (2011)

Predicting Harms and Benefits in Translational Trials: Ethics, Evidence, and Uncertainty

PLoS Medicine, 8

R. Dresser (2009)

First-in-Human Trial Participants: Not a Vulnerable Population, but Vulnerable Nonetheless

The Journal of Law, Medicine & Ethics, 37

(KurzrockR, BenjaminRS Risks and benefits of phase 1 oncology trials, revisited. New Engl J Med 2005;352:930–2. 10.1056/NEJMe05800715745986)

KurzrockR, BenjaminRS Risks and benefits of phase 1 oncology trials, revisited. New Engl J Med 2005;352:930–2. 10.1056/NEJMe05800715745986

KurzrockR, BenjaminRS Risks and benefits of phase 1 oncology trials, revisited. New Engl J Med 2005;352:930–2. 10.1056/NEJMe05800715745986, KurzrockR, BenjaminRS Risks and benefits of phase 1 oncology trials, revisited. New Engl J Med 2005;352:930–2. 10.1056/NEJMe05800715745986

(HarrisJ Scientific research is a moral duty. J Med Ethics 2005;31:242–8. 10.1136/jme.2005.01197315800367)

HarrisJ Scientific research is a moral duty. J Med Ethics 2005;31:242–8. 10.1136/jme.2005.01197315800367

HarrisJ Scientific research is a moral duty. J Med Ethics 2005;31:242–8. 10.1136/jme.2005.01197315800367, HarrisJ Scientific research is a moral duty. J Med Ethics 2005;31:242–8. 10.1136/jme.2005.01197315800367

David Archard (2010)

Whose body is it anyway? Justice and the integrity of the person

Contemporary Political Theory, 9

(ZoharS, O'QuigleyJ Re: Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 2009;101:1732–3; author reply 33–5 10.1093/jnci/djp40019893006)

ZoharS, O'QuigleyJ Re: Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 2009;101:1732–3; author reply 33–5 10.1093/jnci/djp40019893006

ZoharS, O'QuigleyJ Re: Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 2009;101:1732–3; author reply 33–5 10.1093/jnci/djp40019893006, ZoharS, O'QuigleyJ Re: Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 2009;101:1732–3; author reply 33–5 10.1093/jnci/djp40019893006

S. Koyfman, M. Agrawal, E. Garrett-Mayer, Benjamin Krohmal, Elizabeth Wolf, E. Emanuel, C. Gross (2007)

Risks and benefits associated with novel phase 1 oncology trial designs

Cancer, 110

Y. Lo, Carissa Chu, J. Ananworanich, J. Excler, J. Tucker (2015)

Stakeholder Engagement in HIV Cure Research: Lessons Learned from Other HIV Interventions and the Way Forward.

AIDS patient care and STDs, 29 7

(PurcellDF, ElliottJH, RossAL, et al Towards an HIV cure: science and debate from the International AIDS Society 2013 symposium. Retrovirology 2013;10:134 10.1186/1742-4690-10-13424224983)

PurcellDF, ElliottJH, RossAL, et al Towards an HIV cure: science and debate from the International AIDS Society 2013 symposium. Retrovirology 2013;10:134 10.1186/1742-4690-10-13424224983

PurcellDF, ElliottJH, RossAL, et al Towards an HIV cure: science and debate from the International AIDS Society 2013 symposium. Retrovirology 2013;10:134 10.1186/1742-4690-10-13424224983, PurcellDF, ElliottJH, RossAL, et al Towards an HIV cure: science and debate from the International AIDS Society 2013 symposium. Retrovirology 2013;10:134 10.1186/1742-4690-10-13424224983

(KimmelmanJ Gene transfer and the ethics of first-in-human research: lost in translation. Cambridge: Cambridge UP, 2010.)

KimmelmanJ Gene transfer and the ethics of first-in-human research: lost in translation. Cambridge: Cambridge UP, 2010.

KimmelmanJ Gene transfer and the ethics of first-in-human research: lost in translation. Cambridge: Cambridge UP, 2010., KimmelmanJ Gene transfer and the ethics of first-in-human research: lost in translation. Cambridge: Cambridge UP, 2010.

D. Persaud, H. Gay, C. Ziemniak, Y. Chen, M. Piatak, T. Chun, M. Strain, D. Richman, K. Luzuriaga (2013)

Absence of detectable HIV-1 viremia after treatment cessation in an infant.

The New England journal of medicine, 369 19

(AgrawalM, EmanuelEJ Phase I oncology research. In: EmanuelEJ, GradyC, CrouchRA, et al, eds The Oxford textbook of clinical research ethics. Oxford: Oxford UP, 2006:356–66.)

AgrawalM, EmanuelEJ Phase I oncology research. In: EmanuelEJ, GradyC, CrouchRA, et al, eds The Oxford textbook of clinical research ethics. Oxford: Oxford UP, 2006:356–66.

AgrawalM, EmanuelEJ Phase I oncology research. In: EmanuelEJ, GradyC, CrouchRA, et al, eds The Oxford textbook of clinical research ethics. Oxford: Oxford UP, 2006:356–66., AgrawalM, EmanuelEJ Phase I oncology research. In: EmanuelEJ, GradyC, CrouchRA, et al, eds The Oxford textbook of clinical research ethics. Oxford: Oxford UP, 2006:356–66.

J. Leventhal, M. Abecassis, Joshua Miller, L. Gallon, K. Ravindra, D. Tollerud, B. King, M. Elliott, G. Herzig, R. Herzig, S. Ildstad (2012)

Chimerism and Tolerance Without GVHD or Engraftment Syndrome in HLA-Mismatched Combined Kidney and Hematopoietic Stem Cell Transplantation

Science Translational Medicine, 4

M. Avery (2000)

Ethics in Pediatric Research

Pediatric Research, 47

(EmanuelEJ, WendlerD, GradyC What makes clinical research ethical? JAMA 2000;283:2701–11. 10.1001/jama.283.20.270110819955)

EmanuelEJ, WendlerD, GradyC What makes clinical research ethical? JAMA 2000;283:2701–11. 10.1001/jama.283.20.270110819955

EmanuelEJ, WendlerD, GradyC What makes clinical research ethical? JAMA 2000;283:2701–11. 10.1001/jama.283.20.270110819955, EmanuelEJ, WendlerD, GradyC What makes clinical research ethical? JAMA 2000;283:2701–11. 10.1001/jama.283.20.270110819955

(FabreC Whose body is it anyway? Justice and the integrity of the person. Oxford: Oxford University Press, 2008.)

FabreC Whose body is it anyway? Justice and the integrity of the person. Oxford: Oxford University Press, 2008.

FabreC Whose body is it anyway? Justice and the integrity of the person. Oxford: Oxford University Press, 2008., FabreC Whose body is it anyway? Justice and the integrity of the person. Oxford: Oxford University Press, 2008.

(ChenZ, TighiouartM, KowalskiJ Dose escalation with overdose control using a quasi-continuous toxicity score in cancer Phase I clinical trials. Contemp Clin Trials 2012;33:949–58. 10.1016/j.cct.2012.04.00722561391)

ChenZ, TighiouartM, KowalskiJ Dose escalation with overdose control using a quasi-continuous toxicity score in cancer Phase I clinical trials. Contemp Clin Trials 2012;33:949–58. 10.1016/j.cct.2012.04.00722561391, ChenZ, TighiouartM, KowalskiJ Dose escalation with overdose control using a quasi-continuous toxicity score in cancer Phase I clinical trials. Contemp Clin Trials 2012;33:949–58. 10.1016/j.cct.2012.04.00722561391

(HHS. 45 CFR 46 (Human subjects research). USA, 2009.)

HHS. 45 CFR 46 (Human subjects research). USA, 2009.

HHS. 45 CFR 46 (Human subjects research). USA, 2009., HHS. 45 CFR 46 (Human subjects research). USA, 2009.

P. Appelbaum (2007)

Clinical practice. Assessment of patients' competence to consent to treatment.

The New England journal of medicine, 357 18

M. Tighiouart, A. Rogatko, J. Babb (2005)

Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control

Statistics in Medicine, 24

(1998)

National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont report. Secondary the Belmont report

G. Henderson (2015)

The ethics of HIV "cure" research: what can we learn from consent forms?

AIDS research and human retroviruses, 31 1

(PersaudD, GayH, ZiemniakC, et al Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med 2013;369:1828–35. 10.1056/NEJMoa130297624152233)

PersaudD, GayH, ZiemniakC, et al Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med 2013;369:1828–35. 10.1056/NEJMoa130297624152233

PersaudD, GayH, ZiemniakC, et al Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med 2013;369:1828–35. 10.1056/NEJMoa130297624152233, PersaudD, GayH, ZiemniakC, et al Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med 2013;369:1828–35. 10.1056/NEJMoa130297624152233

(HendersonGE The ethics of HIV “cure” research: what can we learn from consent forms? AIDS Res Hum Retroviruses 2015;31:56–63.25406579)

HendersonGE The ethics of HIV “cure” research: what can we learn from consent forms? AIDS Res Hum Retroviruses 2015;31:56–63.25406579

HendersonGE The ethics of HIV “cure” research: what can we learn from consent forms? AIDS Res Hum Retroviruses 2015;31:56–63.25406579, HendersonGE The ethics of HIV “cure” research: what can we learn from consent forms? AIDS Res Hum Retroviruses 2015;31:56–63.25406579

(AppelbaumPS Clinical practice. Assessment of patients’ competence to consent to treatment. N Engl J Med 2007;357:1834–40. 10.1056/NEJMcp074045)

AppelbaumPS Clinical practice. Assessment of patients’ competence to consent to treatment. N Engl J Med 2007;357:1834–40. 10.1056/NEJMcp074045

AppelbaumPS Clinical practice. Assessment of patients’ competence to consent to treatment. N Engl J Med 2007;357:1834–40. 10.1056/NEJMcp074045, AppelbaumPS Clinical practice. Assessment of patients’ competence to consent to treatment. N Engl J Med 2007;357:1834–40. 10.1056/NEJMcp074045

S. Hey, J. Kimmelman (2014)

The Risk-Escalation Model: A Principled Design Strategy for Early-Phase Trials

Kennedy Institute of Ethics Journal, 24

Risks and bene ﬁ ts

C. Tourneau, J. Lee, L. Siu, L. Siu (2009)

Dose Escalation Methods in Phase I Cancer Clinical Trials

JNCI Journal of the National Cancer Institute, 101

(Le TourneauC, LeeJJ, SiuLL Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 2009;101:708–20. 10.1093/jnci/djp07919436029)

Le TourneauC, LeeJJ, SiuLL Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 2009;101:708–20. 10.1093/jnci/djp07919436029

Le TourneauC, LeeJJ, SiuLL Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 2009;101:708–20. 10.1093/jnci/djp07919436029, Le TourneauC, LeeJJ, SiuLL Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 2009;101:708–20. 10.1093/jnci/djp07919436029

Seema Shah, D. Persaud, D. Wendler, Holly Taylor, H. Gay, M. Kruger, C. Grady (2014)

Research into a functional cure for HIV in neonates: the need for ethical foresight.

The Lancet. Infectious diseases, 14 9

(AngellM Medical research: the dangers to the human subjects. The New York Review of Books 2015;62(18).)

AngellM Medical research: the dangers to the human subjects. The New York Review of Books 2015;62(18).

AngellM Medical research: the dangers to the human subjects. The New York Review of Books 2015;62(18)., AngellM Medical research: the dangers to the human subjects. The New York Review of Books 2015;62(18).

(LoB, GradyC, Working Group on Ethics of the International AIDS Society. Ethical considerations in HIV cure research: points to consider. Curr Opin HIV AIDS 2013;8:243–9. 10.1097/COH.0b013e32835ea1c523422260)

LoB, GradyC, Working Group on Ethics of the International AIDS Society. Ethical considerations in HIV cure research: points to consider. Curr Opin HIV AIDS 2013;8:243–9. 10.1097/COH.0b013e32835ea1c523422260, LoB, GradyC, Working Group on Ethics of the International AIDS Society. Ethical considerations in HIV cure research: points to consider. Curr Opin HIV AIDS 2013;8:243–9. 10.1097/COH.0b013e32835ea1c523422260

E. Hayden (2013)

Bid to cure HIV ramps up

Nature, 498

(2017)

J Med Ethics

D. Purcell, J. Elliott, A. Ross, J. Frater (2013)

Towards an HIV cure: science and debate from the International AIDS Society 2013 symposium

Retrovirology, 10

(MillerFG, WertheimerA Facing up to paternalism in research ethics. Hastings Cent Rep 2007;37:24–34. 10.1353/hcr.2007.0044)

MillerFG, WertheimerA Facing up to paternalism in research ethics. Hastings Cent Rep 2007;37:24–34. 10.1353/hcr.2007.0044

MillerFG, WertheimerA Facing up to paternalism in research ethics. Hastings Cent Rep 2007;37:24–34. 10.1353/hcr.2007.0044, MillerFG, WertheimerA Facing up to paternalism in research ethics. Hastings Cent Rep 2007;37:24–34. 10.1353/hcr.2007.0044

(DworkinR What is equality? Part 1: equality of welfare. Philos Public Aff 1981;10:185–246.)

DworkinR What is equality? Part 1: equality of welfare. Philos Public Aff 1981;10:185–246.

DworkinR What is equality? Part 1: equality of welfare. Philos Public Aff 1981;10:185–246., DworkinR What is equality? Part 1: equality of welfare. Philos Public Aff 1981;10:185–246.

(ParfitD On what matters. 1st edn New York: Oxford UP, 2013.)

ParfitD On what matters. 1st edn New York: Oxford UP, 2013.

ParfitD On what matters. 1st edn New York: Oxford UP, 2013., ParfitD On what matters. 1st edn New York: Oxford UP, 2013.

F. Miller, S. Joffe (2008)

Benefit in phase 1 oncology trials: therapeutic misconception or reasonable treatment option?

Clinical Trials, 5

(MillerFG, JoffeS Benefit in phase 1 oncology trials: therapeutic misconception or reasonable treatment option? Clin Trials 2008;5:617–23.19029210)

MillerFG, JoffeS Benefit in phase 1 oncology trials: therapeutic misconception or reasonable treatment option? Clin Trials 2008;5:617–23.19029210

MillerFG, JoffeS Benefit in phase 1 oncology trials: therapeutic misconception or reasonable treatment option? Clin Trials 2008;5:617–23.19029210, MillerFG, JoffeS Benefit in phase 1 oncology trials: therapeutic misconception or reasonable treatment option? Clin Trials 2008;5:617–23.19029210

(TighiouartM, RogatkoA, BabbJS Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control. Stat Med 2005;24:2183–96. 10.1002/sim.210615909291)

TighiouartM, RogatkoA, BabbJS Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control. Stat Med 2005;24:2183–96. 10.1002/sim.210615909291

TighiouartM, RogatkoA, BabbJS Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control. Stat Med 2005;24:2183–96. 10.1002/sim.210615909291, TighiouartM, RogatkoA, BabbJS Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control. Stat Med 2005;24:2183–96. 10.1002/sim.210615909291

(KimmelmanJ, LondonAJ Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty. PLoS Med 2011;8:e1001010 10.1371/journal.pmed.100101021423344)

KimmelmanJ, LondonAJ Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty. PLoS Med 2011;8:e1001010 10.1371/journal.pmed.100101021423344

KimmelmanJ, LondonAJ Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty. PLoS Med 2011;8:e1001010 10.1371/journal.pmed.100101021423344, KimmelmanJ, LondonAJ Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty. PLoS Med 2011;8:e1001010 10.1371/journal.pmed.100101021423344

R. Kurzrock, R. Benjamin (2005)

Risks and benefits of phase 1 oncology trials, revisited.

The New England journal of medicine, 352 9

(WendlerDS The Ethics of pediatric research. New York: Oxford University Press, 2010.)

WendlerDS The Ethics of pediatric research. New York: Oxford University Press, 2010.

WendlerDS The Ethics of pediatric research. New York: Oxford University Press, 2010., WendlerDS The Ethics of pediatric research. New York: Oxford University Press, 2010.

(ShahSK, PersaudD, WendlerDS, et al Research on a cure for HIV in neonates: the need for ethical foresight. 2013 IMPAACT Leadership Retreat. Washington DC, 2013.)

ShahSK, PersaudD, WendlerDS, et al Research on a cure for HIV in neonates: the need for ethical foresight. 2013 IMPAACT Leadership Retreat. Washington DC, 2013.

ShahSK, PersaudD, WendlerDS, et al Research on a cure for HIV in neonates: the need for ethical foresight. 2013 IMPAACT Leadership Retreat. Washington DC, 2013., ShahSK, PersaudD, WendlerDS, et al Research on a cure for HIV in neonates: the need for ethical foresight. 2013 IMPAACT Leadership Retreat. Washington DC, 2013.

(DworkinG The theory and practice of autonomy. Cambridge: Cambridge University Press, 1988.)

DworkinG The theory and practice of autonomy. Cambridge: Cambridge University Press, 1988.

DworkinG The theory and practice of autonomy. Cambridge: Cambridge University Press, 1988., DworkinG The theory and practice of autonomy. Cambridge: Cambridge University Press, 1988.

(LoYR, ChuC, AnanworanichJ, et al Stakeholder Engagement in HIV Cure Research: Lessons Learned from Other HIV Interventions and the Way Forward. AIDS Patient Care STDS 2015;29:389–99.26061668)

LoYR, ChuC, AnanworanichJ, et al Stakeholder Engagement in HIV Cure Research: Lessons Learned from Other HIV Interventions and the Way Forward. AIDS Patient Care STDS 2015;29:389–99.26061668

LoYR, ChuC, AnanworanichJ, et al Stakeholder Engagement in HIV Cure Research: Lessons Learned from Other HIV Interventions and the Way Forward. AIDS Patient Care STDS 2015;29:389–99.26061668, LoYR, ChuC, AnanworanichJ, et al Stakeholder Engagement in HIV Cure Research: Lessons Learned from Other HIV Interventions and the Way Forward. AIDS Patient Care STDS 2015;29:389–99.26061668

R. Dresser (2012)

Building an Ethical Foundation for First-in-Human Nanotrials

The Journal of Law, Medicine & Ethics, 40

John Harris (2005)

Scientific research is a moral duty

Journal of Medical Ethics, 31

E. Emanuel (2008)

The Oxford Textbook of Clinical Research Ethics

S. Zohar, J. O'Quigley (2009)

Re: Dose escalation methods in phase I cancer clinical trials.

Journal of the National Cancer Institute, 101 24

D. Cutas (2007)

Whose Body Is It Anyway? Justice and the Integrity of the Person

Medical Law Review, 15

B. Lo, C. Grady (2013)

Ethical considerations in HIV cure research: points to consider

Current Opinion in HIV and AIDS, 8

(2015)

Medical research: the dangers to the human subjects

(HaydenEC Bid to cure HIV ramps up. Nature 2013;498:417–18. 10.1038/498417a23803820)

HaydenEC Bid to cure HIV ramps up. Nature 2013;498:417–18. 10.1038/498417a23803820

HaydenEC Bid to cure HIV ramps up. Nature 2013;498:417–18. 10.1038/498417a23803820, HaydenEC Bid to cure HIV ramps up. Nature 2013;498:417–18. 10.1038/498417a23803820

J. Velleman (1991)

WELL‐BEING AND TIME

Pacific Philosophical Quarterly, 72

Zhengjia Chen, M. Tighiouart, J. Kowalski (2012)

Dose escalation with overdose control using a quasi-continuous toxicity score in cancer Phase I clinical trials.

Contemporary clinical trials, 33 5

Dana Doan, Barry Knight (2011)

What matters.

Current problems in pediatric and adolescent health care, 41 5

R. Dworkin (1981)

What is Equality? Part 1: Equality of Welfare

, 10

Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

How to keep high-risk studies ethical: classifying candidate solutions

How to keep high-risk studies ethical: classifying candidate solutions

How to keep high-risk studies ethical: classifying candidate solutions

Abstract

Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

How to keep high-risk studies ethical: classifying candidate solutions

How to keep high-risk studies ethical: classifying candidate solutions

How to keep high-risk studies ethical: classifying candidate solutions

Abstract

References (68)

Abstract

Journal

Recommended Articles

There are no references for this article.

Our policy towards the use of cookies